Evaxion receives FDA fast-track designation for personalized cancer immunotherapy
Evaxion Biotech A/S announced that the U.S. Food and Drug Administration (“FDA”) has granted fast track designation for the Company’s personalized cancer therapy, EVX-01, in combination…
Read More...
Read More...